A semi-pharmaceutical approach for the preparation of an anti-IL2 receptor monoclonal antibody in the treatment of acute GvHD in a multicentric study.
A monoclonal antibody against the IL2-Receptor (B-B10) has been developed which inhibits activated T cells. Large batches of B-B10 have been purified from ascites and were checked for the absence of endotoxins, murine DNA and virus before being released for clinical use. Thirty-two patients with corticosteroid-resistant acute Graft versus Host Disease have been treated with B-B10. No side effects were observed and 68% of the patients showed full response to treatment.
Wijdenes
J
J
Centre Regional de Transfusion Sanguine, Besançon, France.
Beliard
R
R
Muot
S
S
Herve
P
P
Peters
A
A
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002478:Cells, Cultured; D002648:Child; D006086:Graft vs Host Disease / Q000628:therapy*; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects; D051379:Mice; D008807:Mice, Inbred BALB C; D015337:Multicenter Studies as Topic; D010865:Pilot Projects; D011817:Rabbits; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D013601:T-Lymphocytes / Q000187:drug effects
D000911:Antibodies, Monoclonal; D015375:Receptors, Interleukin-2